Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
|Videos|September 29, 2020
An Opportunity for Growth
Author(s)Helen Lavretsky, MD, MS
Dr Lavretsky invites us to use the pandemic as a chance to build good habits, explore spiritual avenues, and start new routines.
Advertisement
Dr Lavretsky is Professor of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA.
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Advertisement
Advertisement